IDEAYA Biosciences’s Earnings: A Preview
IDEAYA Biosciences (NASDAQ:IDYA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement.
Analysts estimate that IDEAYA Biosciences will report an earnings per share (EPS) of $-0.31.
IDEAYA And Pfizer Expand Clinical Trial Collaboration and Supply Agreements For Evaluation Of Darovasertib And Crizotinib Combination In Metastatic Uveal Melanoma And Additional cMET-Driven Tumors
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into additional
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Stifel Upgrades IDEAYA Biosciences to Buy, Lowers Price Target to $20
Stifel analyst Benjamin Burnett upgrades IDEAYA Biosciences (NASDAQ:IDYA) from Hold to Buy and lowers the price target from $27 to $20.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
